Regulated
- Risk level
- Highest
- Risk-return
- Bad
- Start from
- €100
iüLabs
Germany
SoluSmart® Technology: Molecular taxis for effective nutritional supplements
Key figures
- Estimated return
- 7.7–11.43×
- platform's estimate
- Valuation
- €12,000,000
- Funding ends
- 30 Jul 2026
- Start from
- €100
- Target
- €1,000,000
What you own, how it can pay off, and when
How can it pay off?
The platform estimates 7.7–11.43×
Usually only if the company is sold or listed. Estimates are the platform's own claims.
Capital at risk. Most startups fail; estimates are the platform's own claims. Shares are hard to sell before an exit.
Would AI invest?
AI 52 MediumOur AI gives this project 52 out of 100: Medium. How the AI score works
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
AI review
AIiüLabs GmbH — Crowdfunding Investor Memo
Premium dietary supplements built on the patented SoluSmart® absorption technology.
Sector: Consumer health / dietary supplements · Stage: Early commercialization (seed) · HQ: Berlin, Germany · Raise: €150K threshold / €1.0M max
|
AI SCORE |
Why this score: |
|
|
|
|
52 / 100 |
|
|
⚠️ Caution |
|
|
|
|
|
|
|
|
ℹ️ This is not investment advice. The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data. |
🏢 Company description
iüLabs GmbH is a Berlin-based dietary-supplement company (HRB 235105 B) founded in 2020 that develops and sells premium supplements built on its patented, exclusively in-licensed SoluSmart® absorption technology, which the company reports forms multilamellar vesicles at preparation to raise the bioavailability of bioactive plant compounds. It currently sells three products directly to consumers via its own webshops — iüVitalizer (cellular energy/fatigue), iüMove (joints/mobility) and iüProtect (immune support) — with a stated pipeline covering menopause, sleep and long COVID. The company reports market entry with iüVitalizer in Q1 2025 and over 1,600 units sold since, a repurchase rate above 40% and a €384 customer lifetime value, all achieved without paid advertising (company-stated, unaudited). The team is led by majority owner Dr. Wolfgang Brysch (CEO & Chief Scientific Officer, 61.86% of shares), with a COO, a chief medical advisor and a UK marketing lead. The round is a profit-participating subordinated loan via FunderNation with a €150K threshold and €1.0M maximum, raising funds for marketing, larger production batches, team expansion and new product development. The issuer set its own €12M pre-money valuation; its most recent (31.12.2024) accounts show an equity-uncovered shortfall.
🎯 Potential returns
|
Target return |
Time horizon |
Target basis |
AI view on reaching this goal |
|
🎯 6.83–9.42x |
⏱ ~5.4 yrs |
Company-provided — the platform/company states a 48–58% p.a. / 6.83–9.42x target with a defined success-, bonus- and exit-interest mechanism tied to the issuer's own plan. |
Plausible only if the company approaches its own aggressive multi-year revenue plan; under neutral or negative scenarios the company states no success interest is paid and principal can be lost. |
📈 Path to target return
|
Company methodology |
Returns are not a fixed coupon. The investor's participation quota (per €100 lent) is applied to (a) the issuer's annual net profit as success interest, (b) a maturity company-value figure for the bonus interest, and (c) net proceeds on a sale of >50% of shares/assets for exit interest. At maturity, company value is set either by the last financing round within 12 months or, absent one, by 300% of the issuer's most recent annual revenue (company-stated). |
|
Comparable exits cited |
Not disclosed in provided materials. |
|
Milestones expected |
Per the company's financial plan: revenue ≈€636K (2026 base case) rising to ≈€2.6M (2027), first positive EBIT in 2027, and ≈€31.7M revenue / €8.7M net profit by 2031 (base case). Use of proceeds: ~35% marketing & sales staff, ~30% external marketing providers, ~30% production materials, ~5% liquidity reserve (company-stated). |
💶 Valuation
|
Pre-money valuation |
€12.0M (issuer-set, before the campaign). |
|
Post-money valuation |
Up to €13.0M at the €1.0M funding maximum (pre-money + amount raised). |
|
Instrument |
Profit-participating subordinated loan (partiarisches Nachrangdarlehen) — debt, not equity. No shares are issued. |
|
How the valuation was set |
Methodology not disclosed in provided materials — the €12M figure is set by the issuer with no comparables or derivation shown. |
|
External benchmarks |
€12M pre-money is roughly 100x the ≈€116K of 2025 plan revenue. No external comparable transaction or third-party valuation was provided; insufficient comparables for this sector and stage in the dossier. |
|
Notable terms |
Investors within 31 days of launch receive a ~12.5% valuation bonus (0.000870% participation per €100 vs 0.000769% later). Issuer bears ~15% of amounts raised in platform/pooling/marketing costs. If the €150K threshold is not met within 90 days, investors are repaid in full without interest. |
📜 Instrument & investor terms
What you own
You are not buying shares. The instrument is a profit-participating subordinated loan (partiarisches Nachrangdarlehen): you lend money to iüLabs and, in return, receive interest linked to the company's profit, value and any sale — but you become a creditor, not a shareholder. Because there is no equity, there is no share class and no shareholder vote: you cannot vote at shareholder meetings or directly influence company decisions, including a decision to sell. Each loan is a direct contract between you and the issuer; for collective matters such as a buy-out or sale negotiation, a pooling arrangement run by FunderNation Support UG provides a voting procedure among loan-holders. In short, your influence…
The full review covers the borrower or company, the security, the cash flow, the risks and a verdict. Sign in to read it.
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
Ask AI about this project
Sign in to ask the AI about this project's documents.
Sign inLike this project?
👍 Yes · 0 👎 No · 0
Comments · 0
- No comments yet.
The platform and similar projects
Offered on
Similar open projects
Kepplair Evolution
Sowefund
- Estimated return
- up to 7×
- platform's estimate
- Valuation
- €60,000,000
Raising €9m
From €500
See project
Wind Fisher
Sowefund
- Estimated return
- up to 10×
- platform's estimate
- Valuation
- €9,961,800
Raising €600k
From €1,000
See project
Blumana
Sowefund
- Estimated return
- up to 28×
- platform's estimate
- Valuation
- €2,799,571
Raising €750k
From €1,000
See project